GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (LTS:0RQE) » Definitions » Investments And Advances

Idorsia (LTS:0RQE) Investments And Advances : CHF0.0 Mil (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia Investments And Advances?

Idorsia's Investments And Advances for the quarter that ended in Sep. 2023 was CHF0.0 Mil.


Idorsia Investments And Advances Historical Data

The historical data trend for Idorsia's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Investments And Advances Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Investments And Advances
Get a 7-Day Free Trial - - - - -

Idorsia Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Idorsia Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Idorsia (LTS:0RQE) Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia (LTS:0RQE) Headlines

No Headlines